Trial
NCT00748163
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Lung Cancer
Intervention
paclitaxel albumin-stabilized nanoparticle formulation
Why stopped
Study has been abandoned for lack of available funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-08